Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibiotics
Research
Shionogi offers $600M for Swiss biotech's antibiotic program
Shionogi and BioVersys will work together to develop new ansamycin candidates for nontuberculous mycobacteria infections.
Darren Incorvaia
Jul 2, 2025 1:00am
GSK's bet on rejected UTI antibiotic pays off with phase 3 win
May 28, 2025 8:42am
Spero halts development on another antibiotic
Mar 28, 2025 7:05am
VC firm launches biotech aiming to counter antibiotic resistance
Feb 24, 2025 7:15am
Basilea opts not to take MRSA antibiotic into clinic
Feb 18, 2025 4:08am
AI-discovered proteins kill bacteria, fungi infecting mice: study
Feb 7, 2025 2:11pm